Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Madan Jagasia, MD MS, Miguel-Angel Perales, MD, Mark A Schroeder, MD, Haris Ali, MD, Nirav N Shah, MD, Yi-Bin Chen, MD, Michael C. Arbushites, Fitzroy Dawkins, MD, Chuan Tian, PhD, Hanna Jean Khoury, MD FACP

Blood (2018) 132 (Supplement 1): 601.

https://doi.org/10.1182/blood-2018-99-116342

Published: 2018

Journal Articles

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 1622.

https://doi.org/10.1182/blood.V128.22.1622.1622

Published: 2016

Journal Articles

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 2793.

https://doi.org/10.1182/blood.V128.22.2793.2793

Published: 2016

Journal Articles

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Jee Hyun Kong, MD, Hanna Jean Khoury, MD, Elliott F. Winton, MD, Leonard T. Heffner, MD, Manila Gaddh, MD, Martha Arellano, MD, Fuad El-Rassi, MD, Audrey S Kim, RN, Anand Jillella, MD, Imre Bodó, MDPhD, Vamsi Kota, MD

Blood (2016) 128 (22): 3093.

https://doi.org/10.1182/blood.V128.22.3093.3093

Published: 2016

Journal Articles

Temperature and Humidity Effects on Acute Vaso-Occlusive Pain Episodes in Sickle Cell Disease

Fuad El Rassi, MD, Eldrida Randall, MS, Sidney F. Stein, MD, Hanna Jean Khoury, MD, James R. Eckman, MD, Morgan L. McLemore, MD

Blood (2015) 126 (23): 992.

https://doi.org/10.1182/blood.V126.23.992.992

Published: 2015

Journal Articles

Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?

Hanna Jean Khoury, MD, Tao Wang, PhD, Mukta Arora, MD, Michael Hemmer, MS, Stephen R. Spellman, MBS, Corey S Cutler, MD MPH, Daniel R. Couriel, MD, Amin M. Alousi, MD, Joseph A. Joseph, MD

Blood (2015) 126 (23): 3132.

https://doi.org/10.1182/blood.V126.23.3132.3132

Published: 2015

Journal Articles

Outcomes of Allogeneic Transplantation in Patients Aged ≤ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR ® Cohort Analysis

Fotios V. Michelis, MDPhD, Vikas Gupta, MD FRCP, FRCPath, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Marcos de Lima, MD, Hanna Jean Khoury, MD, Brenda M Sandmaier, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 2009.

https://doi.org/10.1182/blood.V126.23.2009.2009

Published: 2015

Journal Articles

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Ramesh Balusu, Warren Fiskus, Rekha Rao, Daniel G. Chong, Srilatha Nalluri, Uma Mudunuru, Hongwei Ma, Lei Chen, Sreedhar Venkannagari, Kyungsoo Ha, Sunil Abhyankar, Casey Williams, Joseph McGuirk, Hanna Jean Khoury, Celalettin Ustun, Kapil N. Bhalla

Blood (2011) 118 (11): 3096–3106.

https://doi.org/10.1182/blood-2010-09-309674

Published: 2011

Includes: Supplemental data

Journal Articles

Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).

Bayard L. Powell, MD, Hanna Jean Khoury, MD, Jeffrey H. Lipton, David A. Rizzieri, Denise Williams, MD, A. Robert Turner, MD, FRCPC

Blood (2009) 114 (22): 3295.

https://doi.org/10.1182/blood.V114.22.3295.3295

Published: 2009

Journal Articles

The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated.

Rajni Sinha, MD, MRCP, Jonathan L. Kaufman, MD, Hanna Jean Khoury, Jr., MD, Nassoma King, PA, Pareen J. Shenoy, MBBS, MPH, Carol Lewis, Kevin Bumpers, MPA, Sagar Lonial, MD, Christopher R. Flowers, MD

Blood (2009) 114 (22): 3718.

https://doi.org/10.1182/blood.V114.22.3718.3718

Published: 2009

Journal Articles

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Hanna Jean Khoury, MD, Michael J. Mauro, MD, Yousif Matloub, MD, Tai-Tsang Chen, PhD, Erkut Bahceci, MD, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 1128.

https://doi.org/10.1182/blood.V114.22.1128.1128

Published: 2009

Journal Articles

Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.

Shaozhong Dong, PhD, Sumin Kang, PhD, Sagar Lonial, MD, Hanna Jean Khoury, MD, Jean Viallet, PhD, Jing Chen, PhD

Blood (2007) 110 (11): 2920.

https://doi.org/10.1182/blood.V110.11.2920.2920

Published: 2007

Journal Articles

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells

Shaozhong Dong, Sumin Kang, Ting-Lei Gu, Sean Kardar, Haian Fu, Sagar Lonial, Hanna Jean Khoury, Fadlo Khuri, Jing Chen

Blood (2007) 110 (1): 360–369.

https://doi.org/10.1182/blood-2006-12-065615

Published: 2007

NARROW

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Temperature and Humidity Effects on Acute Vaso-Occlusive Pain Episodes in Sickle Cell Disease

Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?

Outcomes of Allogeneic Transplantation in Patients Aged ≤ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR ® Cohort Analysis

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).

The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated.

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only